All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
The GvHD Hub is pleased to present a visual abstract representing data from a phase II trial (NCT02663622) evaluating CD24Fc, a novel CD24 fusion protein, for graft-versus-host disease prophylaxis.1
This study, which was conducted in two parts (a double-blind dose-escalation phase and an open-label extension phase), evaluated the safety, recommended dose, and efficacy of CD24Fc in patients undergoing allogeneic hematopoietic stem cell transplantation.1 Overall, CD24Fc demonstrated improved graft-versus-host disease-free survival compared with matched controls, and no patients experienced dose-limiting toxicities.1
To download this visual abstract, click below.Download here
Impact of donor clonal hematopoiesis in older matched-related transplantation
The results from a study which evaluated the impact of donor clonal hematopoiesis on the risk of acute graft-versus-host disease (GvHD, aGvHD) and patient outcomes.
Effect of alemtuzumab on GvHD prevention, viral reactivation and T-cell dynamics
The effect of alemtuzumab (Camath-1H) pharmacokinetics on T-cell dynamics, graft-versus-host disease (GvHD) and viral reactivation.
Subscribe to get the best content related to GvHD delivered to your inbox